Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-alpha.

Background: In many digestive diseases the intestinal barrier is weakened by the release of proinflammatory cytokines, including tumour necrosis factor-alpha (TNF alpha).

Aim: To investigate the protective effect of apical diosmectite on the intestinal dysfunction induced by the proinflammatory cytokine TNF alpha.

Methods: Filter grown monolayers of the intestinal cell line HT29-19A were incubated for 48 hours in basal medium containing 10 ng/ml TNF alpha and 5 U/ml interferon-gamma (IFN gamma).

Protective action of diosmectite treatment on digestive disturbances induced by intestinal anaphylaxis in the guinea-pig.

Methods: Colonic transit time, faecal moisture and intestinal permeability were assessed in guinea-pigs sensitized intraperitoneally with cow's milk and challenged with an oral administration of beta-lactoglobulin. One group of animals was treated for 1 week with diosmectite (500 mg.kg/day) and another with placebo.

[Digestive disorders and self medication observed during a competition in endurance athletes. Prospective epidemiological study during a championship of triathlon].

Gastro-intestinal disorders were described during long lasting exercise. However, no systematic evaluation was done before the study of the French Medical Society of Triathlon, which realized an epidemiologic analysis during the French triathlon championship in 1989. The aims of this study were to evaluate the prevalence and the nature of different gastro-intestinal symptoms, to precise the severity and the consequences of these disorders, and to evaluate the self-medication.

Effect of diosmectite on intestinal permeability changes in acute diarrhea: a double-blind placebo-controlled trial.

The effect of diosmectite on intestinal permeability changes in acute diarrhea was measured during a double-blind placebo-controlled trial carried out in 59 Gabonese children aged 5-35 months. Intestinal permeability tests (IPTs), measuring the urinary elimination of orally administered lactulose and mannitol at a dosage of 1 g/10 kg each, were performed during the morning following admission and repeated 2 days later after treatment by diosmectite or placebo. During the first IPT, urine volume and lactulose and mannitol urinary recoveries were comparable in the diosmectite and in the placebo groups: 50 vs.